CVRx (CVRX) Aperçu de l'action
CVRx, Inc. est une société de dispositifs médicaux au stade commercial qui développe, fabrique et commercialise des solutions de neuromodulation pour les patients souffrant de maladies cardiovasculaires aux États-Unis, en Allemagne et dans le monde entier. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 3/6 |
| Croissance future | 1/6 |
| Performances passées | 0/6 |
| Santé financière | 5/6 |
| Dividendes | 0/6 |
Récompenses
Analyse des risques
CVRX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
CVRx, Inc. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$2.88 |
| Plus haut sur 52 semaines | US$11.30 |
| Plus bas sur 52 semaines | US$2.20 |
| Bêta | 0.76 |
| Variation sur 1 mois | 5.49% |
| Variation sur 3 mois | -42.74% |
| Variation sur 1 an | -63.41% |
| Variation sur 3 ans | -80.98% |
| Variation sur 5 ans | -81.02% |
| Évolution depuis l'introduction en bourse | -89.71% |
Nouvelles et mises à jour récentes
Mise à jour du récit • Aug 22
CVRX: Reimbursement Recovery Will Support Bullish Case Despite Sales Execution Challenges
Analysts have trimmed their price targets on CVRx, with one moving from $13 to $5 and others from $12 to $4, citing weaker sales execution, sales force turnover and reimbursement pressure following the latest guidance cuts and Q2 update. Analyst Commentary Recent commentary around CVRx has shifted more cautious as several bearish analysts reassessed their expectations following the Q2 update and guidance reset.Article d’analyse • Aug 09
CVRx, Inc. (NASDAQ:CVRX) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Shareholders in CVRx, Inc. ( NASDAQ:CVRX ) had a terrible week, as shares crashed 54% to US$2.39 in the week since its...Mise à jour du récit • Aug 07
CVRX: Reimbursement Resolution Will Support Bullish Outlook Despite Sales Execution Reset
Analysts cut their price targets on CVRx to $4 from $12, citing lowered fair value estimates and reduced revenue growth expectations following sales force challenges and reimbursement headwinds. Analyst Commentary Recent research on CVRx reflects a more cautious tone from bearish analysts, with attention on both execution risks and the impact on valuation.Recent updates
Mise à jour du récit • Aug 22
CVRX: Reimbursement Recovery Will Support Bullish Case Despite Sales Execution Challenges
Analysts have trimmed their price targets on CVRx, with one moving from $13 to $5 and others from $12 to $4, citing weaker sales execution, sales force turnover and reimbursement pressure following the latest guidance cuts and Q2 update. Analyst Commentary Recent commentary around CVRx has shifted more cautious as several bearish analysts reassessed their expectations following the Q2 update and guidance reset.Article d’analyse • Aug 09
CVRx, Inc. (NASDAQ:CVRX) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Shareholders in CVRx, Inc. ( NASDAQ:CVRX ) had a terrible week, as shares crashed 54% to US$2.39 in the week since its...Mise à jour du récit • Aug 07
CVRX: Reimbursement Resolution Will Support Bullish Outlook Despite Sales Execution Reset
Analysts cut their price targets on CVRx to $4 from $12, citing lowered fair value estimates and reduced revenue growth expectations following sales force challenges and reimbursement headwinds. Analyst Commentary Recent research on CVRx reflects a more cautious tone from bearish analysts, with attention on both execution risks and the impact on valuation.Mise à jour du récit • Jun 16
CVRX: BENEFIT-HF Trial Momentum And Steady Guidance Will Support Bullish Stock Outlook
Analysts have nudged their price target on CVRx slightly higher to $6.00, reflecting modest adjustments to key valuation inputs such as the discount rate, revenue growth expectations, profit margin assumptions, and the forward P/E multiple. What’s in the News for CVRx CVRx began enrollment in the BENEFIT-HF trial, described as one of the largest therapeutic cardiac device studies in heart failure, targeting 2,500 patients across about 150 centers in the U.S. and Germany, with support from CMS Category B IDE coverage.Mise à jour du récit • Jun 02
CVRX: Trial Progress And Steady Guidance Will Likely Cap Near Term Upside Potential
Analysts have modestly adjusted their price target on CVRx, reflecting updated assumptions around fair value at 6.0, a discount rate of 8.35%, revenue growth of 15.41%, profit margin of 12.19%, and a future P/E of 18.62. They are using these revised inputs to fine tune expectations rather than signal a major shift in outlook.Article d’analyse • May 15
The CVRx, Inc. (NASDAQ:CVRX) First-Quarter Results Are Out And Analysts Have Published New Forecasts
Shareholders in CVRx, Inc. ( NASDAQ:CVRX ) had a terrible week, as shares crashed 22% to US$5.74 in the week since its...Mise à jour du récit • May 05
CVRX: Reduced Multiple Expectations Will Likely Constrain Future Share Price Upside
Analysts have reduced their average CVRx price target by $1 to reflect updated views on the company’s risk profile, growth trajectory, profitability expectations, and likely P/E multiple, while keeping fair value broadly in line with prior estimates. Analyst Commentary Recent Street research on CVRx points to a more cautious tone, with the headline takeaways centered on slightly lower price targets and an increased focus on execution and valuation risks.Mise à jour du récit • Apr 19
CVRX: Execution Risks And Updated Assumptions Will Likely Restrain Upside
Analysts have trimmed their price targets on CVRx by $1, citing updated views on discount rates, revenue growth, profit margins, and future P/E assumptions. Analyst Commentary Recent research notes, including one from JPMorgan, point to a more cautious stance on CVRx, reflected in the $1 price target trims.Mise à jour du récit • Mar 31
CVRX: Execution Risks And Recent Price Cuts Will Likely Limit Upside
Analysts have trimmed their CVRx price targets by $1 to reflect updated assumptions around discount rates, revenue growth, profit margins, and future P/E expectations, while maintaining their fair value estimate at $6.00. Analyst Commentary Recent Street research, including updated work from JPMorgan, reflects a more cautious stance on CVRx even as the published fair value estimate remains at $6.00.Mise à jour du récit • Mar 16
CVRX: Execution Risks Around Profitability Path Will Likely Cap Future Upside
Analysts have trimmed their CVRx price targets by $1 to $6, reflecting updated assumptions around revenue growth, discount rate, profit margins, and future P/E expectations. Analyst Commentary Recent research updates point to a more cautious stance on CVRx, with both JPMorgan and other bearish analysts trimming price targets by $1.Mise à jour du récit • Mar 01
CVRX: Reimbursement Progress Will Face Cautious Outlook On Profitability Path
Analysts have trimmed their price target on CVRx by $1, reflecting updated assumptions around discount rates, revenue growth, profit margins and forward P/E that still align with recent Street research from firms that reduced their targets by a similar amount. Analyst Commentary Street research on CVRx has recently centered on slightly lower price targets, including a US$1 trim from JPMorgan, which aligns with similar reductions from other bearish analysts.Article d’analyse • Feb 15
Analysts Are Updating Their CVRx, Inc. (NASDAQ:CVRX) Estimates After Its Full-Year Results
One of the biggest stories of last week was how CVRx, Inc. ( NASDAQ:CVRX ) shares plunged 24% in the week since its...Mise à jour du récit • Feb 15
CVRX: Reimbursement Shift And BENEFIT-HF Trial Will Reshape Long-Term Upside
Analysts have trimmed their CVRx price targets by $1, reflecting updated fair value estimates and assumptions on growth, profitability, and future P/E multiples, while maintaining a constructive view on the story. Analyst Commentary Recent Street research includes price target trims of $1 from both JPMorgan and other bearish analysts, which reflect a more cautious stance on CVRx's risk and reward profile.Article d’analyse • Dec 30
CVRx, Inc.'s (NASDAQ:CVRX) Popularity With Investors Under Threat As Stock Sinks 26%
CVRx, Inc. ( NASDAQ:CVRX ) shareholders won't be pleased to see that the share price has had a very rough month...Article d’analyse • Nov 08
CVRx, Inc. (NASDAQ:CVRX) Released Earnings Last Week And Analysts Lifted Their Price Target To US$11.50
CVRx, Inc. ( NASDAQ:CVRX ) just released its quarterly report and things are looking bullish. CVRx beat expectations...Article d’analyse • Oct 16
After Leaping 39% CVRx, Inc. (NASDAQ:CVRX) Shares Are Not Flying Under The Radar
CVRx, Inc. ( NASDAQ:CVRX ) shares have had a really impressive month, gaining 39% after a shaky period beforehand...Article d’analyse • Sep 16
Does CVRx (NASDAQ:CVRX) Have A Healthy Balance Sheet?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Article d’analyse • Aug 08
Analyst Estimates: Here's What Brokers Think Of CVRx, Inc. (NASDAQ:CVRX) After Its Second-Quarter Report
It's been a sad week for CVRx, Inc. ( NASDAQ:CVRX ), who've watched their investment drop 13% to US$6.94 in the week...Article d’analyse • Jul 15
CVRx, Inc.'s (NASDAQ:CVRX) P/S Is Still On The Mark Following 25% Share Price Bounce
CVRx, Inc. ( NASDAQ:CVRX ) shareholders would be excited to see that the share price has had a great month, posting a...Seeking Alpha • Jul 02
CVRx: Sell-Off Ignores Its True Potential
Summary CVRx offers a unique, FDA-approved heart failure therapy with Medicare reimbursement, positioning it for significant market adoption and growth. The recent share price drop is an overreaction to sales force restructuring and reimbursement fears, while earnings and revenue estimates remain stable. Current valuation is deeply discounted versus sector peers, despite high-teens revenue growth and clear operating leverage potential as sales ramp up. Management insider buying and a net cash balance sheet reinforce my conviction that CVRX is a speculative Buy at these levels. Read the full article on Seeking AlphaArticle d’analyse • Jun 14
Is CVRx (NASDAQ:CVRX) Weighed On By Its Debt Load?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Article d’analyse • May 09
Investors Appear Satisfied With CVRx, Inc.'s (NASDAQ:CVRX) Prospects As Shares Rocket 25%
Those holding CVRx, Inc. ( NASDAQ:CVRX ) shares would be relieved that the share price has rebounded 25% in the last...Seeking Alpha • Apr 09
CVRx, Inc.: Overreaction Creates Buying Opportunity
Summary CVRx, Inc. stock has recently dropped 40%, presenting a buying opportunity as the long-term growth potential remains intact. Barostim has strong clinical results and significant market potential, with a $2.2 billion TAM. Average selling prices can potentially improve as the market recognizes Barostim's effectiveness. CVRX shares are a buy with a price target of $10. Read the full article on Seeking Alpha
Nouveau récit • Mar 29
Expanding 48 US Territories And New Codes Will Broaden Access
Expansion in US territories and implanting centers is expected to drive significant revenue growth and market penetration.Article d’analyse • Mar 07
With A 29% Price Drop For CVRx, Inc. (NASDAQ:CVRX) You'll Still Get What You Pay For
CVRx, Inc. ( NASDAQ:CVRX ) shares have had a horrible month, losing 29% after a relatively good period beforehand...Article d’analyse • Jan 16
Revenues Tell The Story For CVRx, Inc. (NASDAQ:CVRX) As Its Stock Soars 27%
Despite an already strong run, CVRx, Inc. ( NASDAQ:CVRX ) shares have been powering on, with a gain of 27% in the last...Article d’analyse • Dec 26
Does CVRx (NASDAQ:CVRX) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Seeking Alpha • Nov 07
CVRx: Impressive Top-Line Growth Seems Priced In
Summary CVRx's Barostim therapy shows strong clinical success and impressive revenue growth. Recent reimbursement approvals from CMS enhance Barostim's sales potential. Despite double-digit sales growth and a promising product, CVRx's path to profitability is hindered by escalating SG&A costs and potential future shareholder dilution. CVRX is a hold with a price target of $14. Read the full article on Seeking AlphaArticle d’analyse • Nov 01
Analyst Estimates: Here's What Brokers Think Of CVRx, Inc. (NASDAQ:CVRX) After Its Third-Quarter Report
The investors in CVRx, Inc. 's ( NASDAQ:CVRX ) will be rubbing their hands together with glee today, after the share...Article d’analyse • Oct 10
Investors Still Waiting For A Pull Back In CVRx, Inc. (NASDAQ:CVRX)
When you see that almost half of the companies in the Medical Equipment industry in the United States have...Article d’analyse • Jul 31
Does CVRx (NASDAQ:CVRX) Have A Healthy Balance Sheet?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Article d’analyse • Jun 18
Why Investors Shouldn't Be Surprised By CVRx, Inc.'s (NASDAQ:CVRX) 32% Share Price Surge
Those holding CVRx, Inc. ( NASDAQ:CVRX ) shares would be relieved that the share price has rebounded 32% in the last...Article d’analyse • May 04
The Price Is Right For CVRx, Inc. (NASDAQ:CVRX) Even After Diving 47%
To the annoyance of some shareholders, CVRx, Inc. ( NASDAQ:CVRX ) shares are down a considerable 47% in the last month...Rendement pour les actionnaires
| CVRX | US Medical Equipment | US Marché | |
|---|---|---|---|
| 7D | -5.6% | -5.5% | -1.0% |
| 1Y | -63.4% | -19.0% | 14.1% |
Rendement vs Industrie: CVRX a sous-performé le secteur US Medical Equipment qui a rapporté -19.9 % au cours de l'année écoulée.
Rendement vs marché: CVRX a sous-performé le marché US qui a rapporté 13.1 % au cours de l'année écoulée.
Volatilité des prix
| CVRX volatility | |
|---|---|
| CVRX Average Weekly Movement | 20.2% |
| Medical Equipment Industry Average Movement | 8.2% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.9% |
Cours de l'action stable: Le cours de l'action de CVRX a été volatil au cours des 3 derniers mois par rapport au marché US.
Volatilité au fil du temps: La volatilité hebdomadaire de CVRX est passée de 14% à 20% au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 2000 | 223 | Kevin Hykes | www.barostim.com |
CVRx, Inc. est une société de dispositifs médicaux en phase de commercialisation qui développe, fabrique et commercialise des solutions de neuromodulation pour les patients souffrant de maladies cardiovasculaires aux États-Unis, en Allemagne et dans le monde entier. La société propose le Barostim, un dispositif implantable qui délivre des impulsions électriques aux barorécepteurs situés dans la paroi de l'artère carotide pour compenser la diminution de la signalisation des barorécepteurs, et fournit une thérapie d'activation du baroréflexe, qui relie le système cardiovasculaire au système nerveux autonome. Elle vend ses produits par l'intermédiaire d'une force de vente directe, d'agents commerciaux et de distributeurs indépendants.
CVRx, Inc. Résumé des fondamentaux
| CVRX statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$76.19m |
| Bénéfices(TTM) | -US$51.97m |
| Recettes(TTM) | US$61.19m |
1.3x
Ratio P/S-1.5x
Ratio P/ELe site CVRX est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| CVRX compte de résultat (TTM) | |
|---|---|
| Recettes | US$61.19m |
| Coût des recettes | US$8.01m |
| Marge brute | US$53.18m |
| Autres dépenses | US$105.15m |
| Les revenus | -US$51.97m |
Derniers bénéfices déclarés
Jun 30, 2026
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | -1.95 |
| Marge brute | 86.92% |
| Marge bénéficiaire nette | -84.93% |
| Ratio dettes/capitaux propres | 293.5% |
Quelles ont été les performances à long terme de CVRX?
Voir les performances historiques et les comparaisonsAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/09/11 04:06 |
| Cours de l'action en fin de journée | 2026/09/11 00:00 |
| Les revenus | 2026/06/30 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l' qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
CVRx, Inc. est couverte par 9 analystes. 7 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| William Plovanic | Canaccord Genuity |
| Ross Osborn | Cantor Fitzgerald & Co. |
| Sarah James | Cantor Fitzgerald & Co. |